High Tower Advisors, LLC Lineage Cell Therapeutics, Inc. Transaction History
High Tower Advisors, LLC
- $84.5 Billion
- Q3 2025
A detailed history of High Tower Advisors, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 98,370 shares of LCTX stock, worth $186,903. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98,370
Previous 57,706
70.47%
Holding current value
$186,903
Previous $52,000
226.92%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LCTX
# of Institutions
128Shares Held
96MCall Options Held
251KPut Options Held
50K-
Broadwood Capital Inc New York, NY49.6MShares$94.2 Million5.18% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.01MShares$17.1 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.2 Million10.91% of portfolio
-
Comerica Bank4.6MShares$8.74 Million0.03% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $323M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...